Kiora Pharmaceuticals Inc.

KPRX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001372514

None

No letter

4 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $24.3M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	thin data, degenerate inputs not computable: dilution, distress, fortress balance sheet
Inputs computable	4 of 13
Graded from	filings received through Mar 25, 2026 238 days before the rescan; latest periodic filing 10-Q received Nov 12, 2026
Last close	$0.99 2026-11-16; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 25, 2026

We are a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of retinal diseases. We are developing KIO-301, with an initial focus on patients with later stages of vision loss due to retinitis pigmentosa (collectively including any and all sub-forms, "RP"). KIO-301 is a potential vision-restoring small molecule that acts as a "photoswitch" specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including RP. We completed a Phase 1b clinical trial in September 2023 and presented topline results in November 2023 at the American Academy of Ophthalmology Annual Meeting.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 71.8						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.6%			
one or more required annual facts are missing					
Accruals ratio	(2.9%)	(6.7%)	71.8	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 52.3					
Altman Z double-prime	(17.30)	0.31	73.2	705	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(3.61x)			
interest expense must exceed $100,000					
Current ratio	5.99x	2.68x	31.5	781	2025-12-31
Growth and financing, sleeve percentile 32.6					
Revenue growth, three-year compound	not computable	9.6%			
four consecutive annual observations are required					
Free cash flow growth, three-year compound	not computable	11.1%			
four consecutive annual FCF observations are required; found 7					
Reinvestment rate	not computable	33.9%			
NOPAT must exceed $100,000					
Asset growth, three years	9.1%	3.2%	32.6	663	2025-12-31
Net share issuance, one year	not computable	1.6%			
firm-wide XBRL shares cannot be assigned to one ticker class					

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	4 of 13 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-11-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	10.8%	(1.7%)	56
Distance from 52-week high	(67.5%)	(30.5%)	17
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	not computable	0.5%	
Book value to price	not computable	0.28	
Sales to price	not computable	0.36	
Composite equity issuance, five years	not computable	13.5%	
Relative strength against the sector, log excess return	(0.07)	(0.19)	56
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$5.6M
Operating cash flow, four quarters	-$7.8M
Months of runway	8.6
Days since last periodic filing	6 (10-Q received Nov 12, 2026)
Median daily dollar volume, 63 sessions	$39,260

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$10.8M	2025-12-31	2026-03-25	10-K	26-000024
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$10.0M	2025-12-31	2026-03-25	10-K	26-000024
3	assets	us-gaap:Assets	$24.3M	2025-12-31	2026-03-25	10-K	26-000024
4	assets	us-gaap:Assets	$36.5M	2024-12-31	2026-03-25	10-K	26-000024
5	current assets	us-gaap:AssetsCurrent	$21.7M	2025-12-31	2026-03-25	10-K	26-000024
6	current liabilities	us-gaap:LiabilitiesCurrent	$3.6M	2025-12-31	2026-03-25	10-K	26-000024
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$154.2M	2025-12-31	2026-03-25	10-K	26-000024
8	operating income	us-gaap:OperatingIncomeLoss	-$12.8M	2025-12-31	2026-03-25	10-K	26-000024
9	book equity	us-gaap:StockholdersEquity	$16.1M	2025-12-31	2026-03-25	10-K	26-000024
10	liabilities	us-gaap:Liabilities	$8.1M	2025-12-31	2026-03-25	10-K	26-000024
11	operating income	us-gaap:OperatingIncomeLoss	-$12.6M	2023-12-31	2025-03-25	10-K	25-000012
12	interest expense	us-gaap:InterestExpense	$11,132	2023-12-31	2024-03-25	10-K	24-000026
13	revenue	us-gaap:Revenues	$0	2025-12-31	2026-03-25	10-K	26-000024
14	revenue	us-gaap:Revenues	$16.0M	2024-12-31	2026-03-25	10-K	26-000024
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$0	2021-12-31	2022-07-07	10-K/A	22-001931
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$12,059	2020-12-31	2022-07-07	10-K/A	22-001931
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$110,789	2025-12-31	2026-03-25	10-K	26-000024
18	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$24,801	2025-12-31	2026-03-25	10-K	26-000024
19	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$12.1M	2025-12-31	2026-03-25	10-K	26-000024
20	income tax	us-gaap:IncomeTaxExpenseBenefit	-$1.3M	2025-12-31	2026-03-25	10-K	26-000024
21	current assets	us-gaap:AssetsCurrent	$29.7M	2024-12-31	2026-03-25	10-K	26-000024
22	current liabilities	us-gaap:LiabilitiesCurrent	$6.0M	2024-12-31	2026-03-25	10-K	26-000024
23	assets	us-gaap:Assets	$13.7M	2023-12-31	2025-03-25	10-K	25-000012
24	assets	us-gaap:Assets	$18.7M	2022-12-31	2024-03-25	10-K	24-000026

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.